Free Trial
→ Hey, it's Jon Najarian. The SpaceX IPO is right around the corner. But I discovered Elon may have something BIGGER planned. Check this out before June 9th... (From Banyan Hill Publishing) (Ad)tc pixel
NASDAQ:PULM

Pulmatrix Q4 2024 Earnings Report

Pulmatrix logo
$1.36 +0.01 (+1.12%)
As of 05/22/2026 04:00 PM Eastern
This is a fair market value price provided by Massive. Learn more.
ProfileEarnings HistoryForecast

Pulmatrix EPS Results

Actual EPS
-$0.54
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Pulmatrix Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Pulmatrix Announcement Details

Quarter
Q4 2024
Date
3/21/2025
Time
Before Market Opens
Conference Call Date
Friday, March 21, 2025
Conference Call Time
8:00AM ET

Upcoming Earnings

Pulmatrix's Q2 2026 earnings is estimated for Wednesday, August 12, 2026, based on past reporting schedules

Conference Call Resources

Powered by Quartr

Earnings Documents

Pulmatrix's Q4 2024 Press ReleasePress Release
(8-K)
Pulmatrix's Q4 2024 Annual reportAnnual report
(10-K)

Pulmatrix Earnings Headlines

Pulmatrix Inc.: Pulmatrix Announces First Quarter 2026 Financial Results
May 15, 2026  |  finanznachrichten.dehttps://www.finanznachrichten.de/nachrichten-2026-05/68509287-pulmatrix-inc-pulmatrix-announces-first-quarter-2026-financial-results-008.htm
Pulmatrix Inc : PULM
May 15, 2026  |  247wallst.comhttps://247wallst.com/companies/pulm/
Hey, it's Jon Najarian. The SpaceX IPO is right around the corner. But I discovered Elon may have something BIGGER planned. Check this out before June 9th...
After being invited to the SpaceX launch headquarters in Cape Canaveral from one of Elon's top lobbyists… Hall of Fame Trader Jon Najarian now says EVERYONE is missing an even bigger story about the SpaceX IPO… That it's just the start of an Elon Musk $44 trillion "Superconvergence…" An event that could kick off as soon as June 12th.tc pixel
May 26 at 1:00 AM  |  Banyan Hill Publishing (Ad)
Pulmatrix Announces First Quarter 2026 Financial Results
May 15, 2026  |  prnewswire.comhttps://www.prnewswire.com/news-releases/pulmatrix-announces-first-quarter-2026-financial-results-302773027.html
Pulmatrix Announces Closing of Preferred Stock Transaction as Part of Planned Merger
April 21, 2026  |  prnewswire.comhttps://www.prnewswire.com/news-releases/pulmatrix-announces-closing-of-preferred-stock-transaction-as-part-of-planned-merger-302748188.html
PULM Stock Alert: Halper Sadeh LLC is Investigating Whether Pulmatrix, Inc. is Obtaining a Fair Price for its Shareholders
April 13, 2026  |  businesswire.comhttps://www.businesswire.com/news/home/20260413345444/en/pulm-stock-alert-halper-sadeh-llc-is-investigating-whether-pulmatrix-inc.-is-obtaining-a-fair-price-for-its-shareholders/
See More Pulmatrix Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Pulmatrix? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Pulmatrix and other key companies, straight to your email.

About Pulmatrix

Pulmatrix (NASDAQ:PULM) is a clinical-stage biopharmaceutical company dedicated to developing inhaled therapies for patients suffering from respiratory diseases. The company’s proprietary iSPERSE® dry-powder formulation platform produces fine microparticles optimized for deep-lung delivery, rapid absorption and consistent dosing, addressing challenges often encountered with traditional inhalation approaches.

Among Pulmatrix’s lead programs is PUR1900, an inhaled therapy designed to treat pulmonary fungal infections such as allergic bronchopulmonary aspergillosis (ABPA). Another key candidate, PLX100, is being investigated for pulmonary sarcoidosis, a chronic inflammatory disease of the lungs. Both programs have progressed through preclinical and early clinical stages, demonstrating favorable tolerability profiles and the potential to reduce systemic side effects.

Founded in 2005 and headquartered in Lexington, Massachusetts, Pulmatrix combines formulation science with pulmonary pharmacology to advance its pipeline. The company collaborates with leading academic institutions and clinical research centers across the United States to conduct studies in diverse patient populations, leveraging its R&D infrastructure to support efficient development pathways.

Pulmatrix’s leadership team brings extensive experience in respiratory drug development and regulatory strategy. Focused on advancing its inhaled therapies through pivotal trials and strategic partnerships, the company aims to expand its portfolio into additional acute and chronic respiratory conditions, ultimately improving patient outcomes and quality of life.

View Pulmatrix Profile
Earnings Tools